Accelerating Biopharmaceutical Development with CE-MS - Takeaway - MDSpire
Feature

Accelerating Biopharmaceutical Development with CE-MS

Microfluidic CE-MS interfaces simplifies and streamlines biotherapeutic characterization to reduce turnaround times in bioanalytical labs

  • April 30, 2026

  • 7 min

Share

  • 1

    Biopharmaceutical companies face pressure for faster development.

  • 2

    LC-MS methods are standard but time-consuming.

  • 3

    CE-MS offers a compact solution for biotherapeutic analysis.

  • 4

    Direct interfaces like ZipChip ease integration into workflows.

  • 5

    CE-MS provides faster turnaround for early development samples.

Original Source(s)

Accelerating Biopharmaceutical Development with CE-MS

  • April 30, 2026

Related Content

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of tria...

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...